Prevalence of perfusion defects detected by stress 99mtechnetium sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with breast cancer
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24982388
PII: 34/7/3689
Knihovny.cz E-resources
- Keywords
- Atherosclerosis, breast cancer, single-photon emission computed tomography,
- MeSH
- Adult MeSH
- Tomography, Emission-Computed, Single-Photon methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Breast Neoplasms diagnostic imaging physiopathology MeSH
- Coronary Artery Disease diagnostic imaging physiopathology MeSH
- Radiopharmaceuticals MeSH
- Aged MeSH
- Technetium Tc 99m Sestamibi MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Radiopharmaceuticals MeSH
- Technetium Tc 99m Sestamibi MeSH
AIM: The aim of the present study was to investigate myocardial perfusion in relation to disease history and laboratory parameters of atherosclerosis risk in asymptomatic patients with breast carcinoma. PATIENTS AND METHODS: One-hundred and eighty-one patients with breast carcinoma were studied. Myocardial perfusion was assessed using single-photon emission computed tomography (SPECT) with 99mtechnetium sestamibi. RESULTS: Perfusion defects were detected in 12 patients (7%). Higher body-mass index, increased concentrations of D-dimers, C-reactive protein, fibrinogen, glucose, triglycerides, and urinary albumin, a history of hypertension and of radiotherapy to the left chest wall were all associated with increased risk of perfusion defects. In a multivariate stepwise selection logistic regression model, body mass index, albuminuria and radiotherapy to the left hemithorax were significantly associated with the presence of perfusion defects. CONCLUSION: In addition to other factors, treatment history may be associated with the presence of perfusion defects in patients with breast cancer.
